Synergy CHC Corp (SNYR): Broker Consensus Forecast

Corporate company logo of Synergy CHC Corporation (SNYR)

Synergy CHC Corp (SNYR) is scaling its wellness asset network through digital sales, leveraging the acquisition of profitable cosmetics brands that ensure a steady cash flow due to customer loyalty. This price chart reflects a current level of 3.73. However, the marketing environment is becoming more complex: customer acquisition costs are rising, and inflation within the DTC segment is triggering a partial churn of the audience.

SNYR Synergy CHC Corp. Price Target Chart (10/24/2024 - 10/03/2026)
Flagship merchandise of Synergy CHC

Investors utilize this indicator to determine an asset's fair value based on aggregated fundamental models from professional analysts. The average target price, which forms the consensus target for the stock, reflects the growth potential of Synergy CHC Corp (SNYR), given the multi-profile holding's resilience driven by brand diversification within the beauty and health sector and omnichannel distribution.

Competitors of Synergy CHC Corp

Analyst Median Target haleon.com|Price Target Chart Kenvue KVUE|VRNA: Broker Consensus Forecast|MENS: Consensus Target|Average Forecast Price Ligand Corp|Amneal Pharmaceuticals (AMRX) - Price Target Chart|perrigo.com - Fair Value Consensus|Price Target Chart Alvotech SA|Liquidia Corp - Forecast Levels Chart|Analyst Consensus Forecast GLPG|ANIP (ANI Pharmaceuticals Corp) - Fair Value Consensus|Analyst Consensus Forecast MNKD (MannKind Corporation)|Analyst Consensus Forecast amphastar.com AMPH|PCRX - Price Target Chart|Fair Value Consensus SPRY (ARS Pharmaceuticals Inc)|Theravance (TBPH) - Price Target Chart|Consensus Target Aquestive Corp|SCPH (scPharmaceuticals, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Tectonic|Consensus Target TNXP (Tonix Pharmaceuticals Holding Corp.)|SXTC (sxtchina.com) - Fair Value Consensus|Price Target Chart Eupraxia Pharmaceuticals Inc. EPRX|BioHarvest Sciences Inc (BHST) - Average Forecast Price|EXOZ: Consensus Target|Oramed Pharmaceuticals - Analyst Forecast Prices|ENTX: Analyst Consensus Forecast|MindWalk Holdings, Inc. - Fair Value Consensus|ABVC (ABVC BioPharma Inc) - Analyst Consensus Forecast|Average Forecast Price Cumberland Corp CPIX|Price Target Chart Quantum BioPharma Ltd (QNTM)|FGEN (fibrogen.com) - Fair Value Consensus|Price Target Chart Telomir Pharmaceuticals, Inc. TELO|Analyst Median Target Rani Therapeutics Holdings (RANI)|RLYB: Consensus Target|Average Forecast Price Lexaria Bioscience|Pulmatrix, Inc. (PULM) - Price Target Chart|Broker Consensus Forecast PTHL|APM (Aptorum Group Ltd) - Analyst Consensus Forecast|Average Forecast Price Lyra Therapeutics Inc. LYRA|Price Target Chart Impact BioMedical Inc (IBO)|TNFA (tnfpharma.com) - Fair Value Consensus|Analyst Consensus Forecast YCBD (cbdMD)|Analyst Target Range painreform.com|CYTO: Consensus Target|Average Forecast Price Lipella Pharmaceuticals Inc|OPTN (Optinose) - Consensus Target|Pieris Pharma - Fair Value Consensus|PROC (Procaps Group S.A.) - Analyst Consensus Forecast|Consensus Target petrospharma.com (PTPI)|Analyst Consensus Forecast QLI|SLRN (Acelyrin Inc.) - Fair Value Consensus|Analyst Consensus Forecast TFFP (TFF Pharma)